Pharmacists' specialized training and knowledge qualify them to lead and engage in research pertaining to optimal medication use. Performing research promotes pharmacy professionalism and fosters interdisciplinary collaboration. To conduct research appropriately, one must have thorough knowledge of when institutional review board (IRB) approval is required and how to successfully navigate IRB processes. The overarching mission of the IRB overseeing research at an organization per federal guidelines is to protect the rights and welfare of human subjects participating in research. This article discusses the following general pharmacy practice–based considerations relating to IRB processes: strategies for developing research projects, key distinctions between quality improvement and research, practical considerations for submitting IRB applications and documentation, different categories of IRB submission, informed consent and conditions for waivers or alterations of consent, and principal investigator obligations for approved research. Pharmacists should also account for organization-specific IRB processes when designing, submitting, and implementing research projects.
American Society of Hospital Pharmacists.ASHP guidelines for pharmaceutical research in organized health-care settings. Am J Hosp Pharm.1989; 46: 129–130.
2.
WeberR.J., CobaughD.J.Developing and executing an effective research plan. Am J Health Syst Pharm.2008; 65(21): 2058–2065.
Department of Health and Human Services.Office for Human Research Protections (OHRP). Code of Federal Regulations Title 45, Part 46. HHS policy for protection of human subjects, revised January 15, 2009. http://www.hhs.gov/ohrp/policy/ohrpregulations.pdf. Accessed June 12, 2015.
9.
Department of Health and Human Services.Office for Human Research Protections (OHRP). Federal Policy for the protection of human subjects (common rule). www.hhs.gov/ohrp/humansubjects/commonrule/. Accessed June 17, 2015.
10.
BarlettaJ.F.Conducting a successful residency research project. Am J Pharm Educ.2008; 72(4): Article 92, 1–7.
ByerlyW.Working with the institutional review board. Am J Health Syst Pharm.2009; 66: 176–184.
20.
Department of Health and Human Services.Office for Human Research Protections (OHRP). Human subjects regulations decision charts. September 24, 2004 www.hhs.gov/ohrp/policy/checklists/decisioncharts.html. Accessed June 17, 2015.
PogorzelskaM., StoneP.W., CohnE.G., LarsonE.Changes in the institutional review board submission process for multicenter research over 6 years. Nurs Outlook.2010; 58: 181–187.
Paasche-OrlowM.K., TaylorH.A., BrancatiF.L.Readability standards for informed consent forms as compared to actual readability. New Engl J Med.2003; 348: 721–726.
35.
MalikL., KuoJ., YipD., MejiaA.How well informed is the informed consent in cancer clinical trials. Clin Trials.2014; 11: 686–688.
HudsonK.L., CollinsF.S.Bringing the common rule into the 21st century. N Engl J Med.2015; 373: 2293–2296.
39.
KirshS., WuW., EdelmanD., AronD.C.Research versus quality improvement: Distinct or a distinction without a difference? A case study comparison of two studies. Jt Comm J Qual Patient Saf.2014; 40(8): 365–375.
